Juno Therapeutics (JUNO) to Highlight New Advances in CD19- and BCMA-Targeted CAR T Therapy at ASH – StreetInsider.com
Endpoints News |
Juno Therapeutics (JUNO) to Highlight New Advances in CD19- and BCMA-Targeted CAR T Therapy at ASH
StreetInsider.com “The presentations at ASH will showcase promising data coming from our pipeline of CD19- and BMCA-directed CAR T cell product candidates,” said Sunil Agarwal, M.D., Juno's President of Research and Development. "Results from the ongoing … #ASH17: The big loser in CAR–T, Juno is making a bid to seize the fast lane to frontrunner status Head-To-Head Contrast: Juno Therapeutics (NASDAQ:JUNO) versus Its Rivals |
